David T Teachey MD
Professor at Children's Hospital of Philadelphia and University of Pennsylvania Perelman School of Medicine
Join to View Full Profile
3401 Civic Center Blvd# ChildrenPhiladelphia, PA 19104
Phone+1 215-590-3535
Fax+1 215-590-3992
Dr. Teachey is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. David Teachey is a specialist in Pediatric Hematology & Oncology based in Philadelphia, PA. He completed his residency at Children's National Medical Center and further enhanced his skills at Children's Hospital of Philadelphia. With his extensive experience in lymphoblastic leukemia, lymphoma, and autoimmune diseases, he currently serves as a Professor at the Perelman School of Medicine and as an Attending Physician at the Children's Hospital of Philadelphia.
Education & Training
Children's Hospital of Philadelphia2005
Children's National HospitalResidency, Pediatrics, 1999 - 2002
Eastern Virginia Medical SchoolClass of 1999
Certifications & Licensure
FL State Medical License 2021 - Present
PA State Medical License 2002 - 2026
VA State Medical License 2021 - 2024
NY State Medical License 2021 - 2023
NC State Medical License 2020 - 2022
DC State Medical License 2001 - 2004
American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Sirolimus for Autoimmune Disease of Blood Cells Start of enrollment: 2006 Dec 01
- Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH) Start of enrollment: 2013 Dec 01
- Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma Start of enrollment: 2014 Oct 04
Publications & Presentations
PubMed
- μPharma: A microfluidic, AI-driven pharmacotyping platform for single-cell drug sensitivity prediction in leukemia.Huiqian Hu, Huanbin Zhao, Ping Lu, Teng Ma, Satoshi Yoshimura
Med. 2026-03-13 - Deregulation of FOXF1/FENDRR from t(14;16)(q32;q24) defines a subtype of high-risk lineage ambiguous leukemia.Danika Di Giacomo, Petri Pölönen, Valentina Bardelli, Shunsuke Kimura, Valentina Pierini
Blood. 2026-03-06 - CCR4 expression defines a targetable subset of T-cell acute lymphoblastic leukemia.Jason Xu, Michael McCoy, Zachary Martinez, Jonathan H Sussman, Daniel Gao
Blood Advances. 2026-02-11
Journal Articles
- Targeting EIF4E Signaling with Ribavirin in Infant Acute Lymphoblastic LeukemiaNyla A Heerema, James W Davenport, Carolyn A Felix, Andrew J Carroll, ZoAnn E Dreyer, Alix E Seif, David T Teachey, Joanne M Hilden, Sarah K Tasian, Cheryl L Willman, ..., Nature
Authored Content
- Blinatumomab Added to Chemotherapy Improves Disease-Free Survival in Newly Diagnosed NCI Standard Risk Pediatric B-acute Lymphoblastic Leukemia: Results from the Randomized Children’s Oncology Group Study AALL1731December 2024
Press Mentions
One Size Doesn’t Fit ALL: Dynamic Approaches to Childhood LeukemiaNovember 20th, 2025
Novel Insights May Transform Diagnosis and Treatment of Pediatric Patients with T-lineage ALLOctober 3rd, 2025- Major Data Updates and New Study Broaden the Kids First Data EcosystemSeptember 8th, 2025
Grant Support
- Improving risk allocation and developing novel therapies for children with T-ALL and T-LLCHILDREN'S HOSP OF PHILADELPHIA2015–2028
- Biomarkers of dasatinib response and resistance in T-cell acute lymphoblastic leukemiaST. JUDE CHILDREN'S RESEARCH HOSPITAL2021–2026
- Targeting The Mtor Signaling Pathway In Autoimmune Lymphoproliferative SyndromeNational Institute Of Allergy And Infectious Diseases2011
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
